Author + information
- Cordula M. Felix,
- JiangMing Fam,
- Roberto Diletti,
- Evelyln Regar,
- Nicolas van Mieghem,
- Yoshinobu Onuma and
- Robert Jan van Geuns
To report on long-term clinical outcomes of the ABSORB BVS compared to Xience metallic stent.
Multiple studies have proven feasibility and safety of the Absorb bioresorbable vascular scaffold (BVS). However, data long-term outcomes are limited and often available only for simpler lesions. In July 2016, mid-term outcomes of the BVS Expand registry, a single arm, single center Dutch registry were published.
Patients included in the BVS Expand Registry (in- and exclusion criteria were reported elsewhere) were matched in a 1:2 manner to Xience V patients. Baseline before and after matching were reported and clinical outcomes, described as Kaplan-Meier estimated, at two years were described. For this study, follow-up was extended to 2 years and a comparison with the everolimus-eluting Xience V metal stent was made.
This study reported on 244 BVS patients included in the BVS Expand registry, compared with 488 patients that were treated with Xience V metallic stent, applying propensity score matching. Baseline characteristics before analysis differed significantly for mean age, smoking, dyslipidemia, history of PCI or CABG, multivessel disease, clinical presentation during index procedure and total scaffold/ stent length. After matching, only smoking and history of CABG were different among two groups. During CRT 2017, two years results will be presented.